[1] |
DE KOUCHKOVSKY I, ABDUL-HAY M. Acute myeloid leukemia:a comprehensive review and 2016 update[J]. Blood Cancer J, 2016, 6(7):e441.
DOI
|
[2] |
TSIRIGOTIS P, BYRNE M, SCHMID C, et al. Relapse of AML after hematopoietic stem cell transplantation:methods of monitoring and preventive strategies. A review from the ALWP of the EBMT[J]. Bone Marrow Transplant, 2016, 51(11):1431-1438.
DOI
|
[3] |
BAZARBACHIA, SCHMID C, LABOPIN M, et al. Evaluation of trends and prognosis over time in patients with AML relapsing after allogeneic hematopoietic cell transplant reveals improved survival for young patients in recent years[J]. Clin Cancer Res, 2020, 26(24):6475-6482.
DOI
PMID
|
[4] |
HOROWITZ M, SCHREIBER H, ELDER A, et al. Epidemiology and biology of relapse after stem cell transplantation[J]. Bone Marrow Transplant, 2018, 53(11):1379-1389.
DOI
|
[5] |
MCGOWAN-JORDAN J, SIMONS A, SCHMID M. ISCN 2016:an international system for human cytogenomic nomenclature(2016)[M]. Basel:Karger, 2016.
|
[6] |
ALI A M, MIRRAKHIMOV A E, ABBOUD C N, et al. Leukostasis in adult acute hyperleukocytic leukemia:a clinician's digest[J]. Hematol Oncol, 2016, 34(2):69-78.
DOI
URL
|
[7] |
BEWERSDORF J P, ZEIDAN A M. Hyperleukocytosis and leukostasis in acute myeloid leukemia:can a better understanding of the underlying molecular pathophysiology leadto novel treatments?[J]. Cells, 2020, 9(10):2310.
DOI
URL
|
[8] |
FENG S, ZHOU L, ZHANG X, et al. Impact of ELN risk stratification,induction chemotherapy regimens and hematopoietic stem cell transplantation on outcomes in hyperleukocytic acute myeloid leukemia with initial white blood cell count more than 100×109/L[J]. Cancer Manag Res, 2019, 11:9495-9503.
DOI
URL
|
[9] |
VENTURA G J, HESTER J P, SMITH T L, et al. Acute myeloblastic leukemia with hyperleukocytosis:risk factors for early mortality in induction[J]. Am J Hematol, 1988, 27(1):34-37.
DOI
URL
|
[10] |
RÖLLIG C, EHNINGER G. How I treat hyperleukocytosis in acute myeloid leukemia[J]. Blood, 2015, 125(21):3246-3252.
DOI
PMID
|
[11] |
CANAANI J, LABOPIN M, SOCIE G, et al. Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation:an analysis from the acute leukemia working party of the EBMT[J]. Am J Hematol, 2017, 92(7):653-659.
DOI
URL
|
[12] |
丁文稳. 异基因造血干细胞移植后急性白血病复发的危险因素分析[D]. 郑州: 郑州大学, 2019.
|
[13] |
STENGEL A, KERN W, HAFERLACH T, et al. The impact of TP53 mutations and TP53 deletions on survival varies between AML,ALL,MDS and CLL:an analysis of 3 307 cases[J]. Leukemia, 2017, 31(3):705-711.
DOI
URL
|
[14] |
WELCH J S. Patterns of mutations in TP53 mutated AML[J]. Best Pract Res Clin Haematol, 2018, 31(4):379-383.
DOI
PMID
|
[15] |
BLUM W, BOLWELL B, PHILLIPS G, et al. High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation[J]. Biol Blood Marrow Transplant, 2006, 12(1):61-67.
|
[16] |
LIN C H, CHEN T C, SHIH Y H, et al. Acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation:a retrospective study from a single institution[J]. J Int Med Res, 2022, 50(2):3000605221078466.
|